Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Alex Bramley"'
Publikováno v:
Clinical pharmacology in drug development. 8(2)
Osimertinib is a third-generation, central nervous system-active, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) selective for EGFR-TKI sensitizing and T790M resistance mutations. This phase 1, open-label study (NCT02491944) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d741d3479b3ed11a159bf2009385c02c
https://pubmed.ncbi.nlm.nih.gov/29683562
https://pubmed.ncbi.nlm.nih.gov/29683562
